Most Liquid Pharmaceutical Products Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1AAPG Ascentage Pharma Group
1.05 B
 0.05 
 4.03 
 0.22 
2TLX Telix Pharmaceuticals Limited
745.86 M
 0.01 
 3.83 
 0.05 
3UPB Upstream Bio,
342.19 M
(0.07)
 5.56 
(0.41)
4LSBPW LakeShore Biopharma Co,
201.56 M
 0.08 
 22.47 
 1.85 
5SEPN Septerna, Common Stock
131 M
(0.12)
 9.09 
(1.13)
6MAZE Maze Therapeutics, Common
119.49 M
(0.19)
 5.54 
(1.06)
7MTVA MetaVia
16.15 M
(0.11)
 8.38 
(0.91)
8NEUP Neuphoria Therapeutics
13.12 M
 0.18 
 4.96 
 0.90 
9DWTX Dogwood Therapeutics,
10.9 M
 0.12 
 50.57 
 6.32 
10EXOZ eXoZymes,
10.21 M
 0.04 
 6.23 
 0.28 
11MRNA Moderna
8.35 B
(0.06)
 5.04 
(0.30)
12DNLI Denali Therapeutics
1.07 B
(0.15)
 4.75 
(0.71)
13MRVI Maravai Lifesciences Holdings
617.45 M
(0.30)
 5.06 
(1.50)
14DVAX Dynavax Technologies
518.17 M
(0.10)
 2.34 
(0.22)
15VNDA Vanda Pharmaceuticals
440.86 M
 0.01 
 2.64 
 0.04 
16MRUS Merus BV
376.11 M
 0.04 
 3.76 
 0.17 
17DSGN Design Therapeutics
359.38 M
(0.10)
 5.55 
(0.53)
18VALN Valneva SE ADR
336.22 M
 0.14 
 6.09 
 0.84 
19VERV Verve Therapeutics
293.56 M
(0.03)
 7.60 
(0.23)
20MOLN Molecular Partners AG
267.13 M
(0.14)
 4.36 
(0.62)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).